Abstract
Rationale
The subjective, psychomotor, and physiological effects of a widely prescribed and abused prescription opioid, oxycodone, have not been studied in a population of non-drug-abusing people.
Objectives
To characterize the effects of oxycodone in non-drug-abusing volunteers.
Methods
Eighteen volunteers participated in a crossover, randomized, double-blind study in which they received, all p.o., placebo, 10 mg oxycodone, 20 mg oxycodone, 30 mg oxycodone, 40 mg morphine, and 2 mg lorazepam. Measures were assessed before and for 300 min after drug administration. End-of-session and 24-h post-session measures were taken to assess residual drug effects and overall subjects' assessments of the drug effects.
Results
Subjective effects of oxycodone were dose related, with the majority of statistically significant effects limited to the two higher doses tested. Oxycodone produced a profile of subjective effects that included both pleasant and unpleasant effects. Morphine in general produced effects similar in magnitude to those of 10 mg and 20 mg oxycodone. Peak liking and drug-wanting ratings were increased by all doses of oxycodone and by morphine, and trough ratings of liking (dislike) were lower in the 20-mg and 30-mg oxycodone conditions, relative to the placebo condition. Post-session ratings of overall liking and drug wanting were not statistically significant, either at the end of the session or 24 h later. Cognitive and psychomotor impairment were obtained with the higher doses of oxycodone, but to a much lesser degree than that of lorazepam. Miosis and exophoria were increased in a dose-related manner by oxycodone.
Conclusions
Oxycodone produced effects similar to those of other mu opioid agonists. Although oxycodone produced abuse liability-related subjective effects, it also produced unpleasant effects, a phenomenon we have observed in other opioid studies in non-drug-abusing volunteers.
Similar content being viewed by others
References
Aceto MD, Kipps BR, Harris LS, Bowman ER (2002) Updated studies on oxycodone, the active ingredient of the controlled-release formulation. Oxy Contin Drug Alcohol Depend 66 [Suppl 1]:S2
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders-IV. American Psychiatric Association, Washington
Baddeley AD (1968) A three-minute reasoning test based on grammatical transformation. Psychonomic Sci 10:341–342
Black ML, Hill JL, Zacny JP (1999) Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers. Anesthesiology 90:718–726
Cleary J, Mikus G, Somogyi A, Bochner F (1994) The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley dark agouti rat model. J Pharmacol Exp Ther 271:1528–1534
Curran HV, Allen D, Lader M (1987) The effects of single doses of alpidem and lorazepam on memory and psychomotor performance in normal volunteers. J Psychopharmacol 2:81–89
Curtis GB, Johnson GH, Clark P, Taylor R, Brown J, O'Callaghan R, Shi M, Lacouture PG (1999) Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55:425–429
Deneau G, Seevers MH (1957) Studies in the monkey (Macacca mulatta) designed to determine the value of this animal for predicting addiction liability to the newer synthetic analgesics. Bull Drug Addiction Narcotics, Appendix N, pp 1709–1710
Derogatis LR, Lipman RS, Cozi L (1973) HSCL-90: An outpatient psychiatric rating scale-a preliminary report. Psychopharmacol Bull 9:13–17
Dykstra LA, Preston KL, Bigelow GE (1997) Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology 130:14–27
Falk E (1917) Eukodal, ein neues narkoticum. Muenchener Med Wochenschr 64:381–384
Foley KM (1985) The treatment of cancer pain. N Engl J Med 313:84–95
Fraser HF, van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (a) "attitude" of opiate addicts toward opiate-like drugs, (b) a short-term "direct" addiction test. J Pharmacol Exp Ther 133:371–387
Haertzen CA (1966) Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 18:163–194
Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. BMJ 3:132–135
Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37–45
Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in normal volunteers. Psychopharmacology 152:31–39
Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheimer PD (1996) pharmacokinetic–pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52–61
Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639–646
Levy MH (1996) Pharmacological treatment of cancer pain. N Engl J Med 335:1124–1132
Martin WR, Gorodetszky CW, Kay DC, McClane TK, Jasinski DR (1966) Activities of the addiction research center during 1965. Appendix 19. In: Committee on problems of drug dependence. Minutes of the 28th meeting, National Academy of Sciences, National Research Council, Washington, DC, pp 4658–4660
Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258
Miaskowski C, Levine JD (1999) Does opioid analgesia show a gender preference for females? Pain Forum 8:34–44
Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2:239–249
Nuotto EJ, Korttila K (1991) Evaluation of a new computerized psychomotor test battery: effects of alcohol. Pharmacol Toxicol 68:360–365
O'Hanlon JF, Vermeeren A, Uiterwijk MMC, van Veggel LMA, Swijgman HF (1995) Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology 31:81–88
O'Neill WM, Hanks GW, White L, Simpson P, Wesnes K (1995) The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 48:447–453
Paivio A, Yulle JC, Madigan SA (1968) Concreteness, imagery, and meaningfulness values for 925 nouns. J Exp Psychol 76S:1–25
Petry NM, Bickel WK, Huddleston J, Tzanis E, Badger GJ (1998) A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users. Drug Alcohol Depend 50:129–136
Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63–67
Preston KL, Jasinski DR (1991) Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28:49–82
Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184–196
Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73:151–157
Selzer ML (1971) The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127:89–94
Seppala K, Korttila K, Hakkinene S, Linnoila M (1976) Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol 3:831–841
Silvasti M, Rosenberg P, Seppala T, Svartling N, Pitkanen M (1998) Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 42:576–580
Subhan Z, Harrison C, Hindmarch I (1986) Alprazolam and lorazepam: single and multiple-dose effects on psychomotor skills and sleep. Eur J Clin Pharmacol 29:709–712
Substance Abuse and Mental Health Services Administration (SAMHSA) (2002a) Office of Applied Studies. Results from the 2001 National Household Survey on Drug Abuse, volume II. Technical appendices and selected data tables. NHSDA Series H-18, DHHS Publication No. SMA 02–3759, Rockville, MD
Substance Abuse and Mental Health Services Administration (SAMHSA) (2002b) Office of Applied Studies. Emergency department trends from the Drug Abuse Warning Network, final estimates 1994–2001. DAWN Series D-21, DHHS Publication No. SMA 02–3635, Rockville, MD
Swain HH, Fly CL, Seevers MH (1977) Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey. Proceedings of the 39th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, pp 614–636
Thorndike EL, Lorge L (1944) The teacher's word book of 30,000 words. Columbia University Press, New York
Walker DJ, Zacny JP (1999) Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289:1454–1464
Wechsler D (1958) The measurement and appraisal of adult intelligence. Williams and Wilkins, Baltimore
Wetherell A (1996) Performance tests. Environ Health Perspect 104 [Suppl 2]:247–273
Woods JH, Ko MC, Winger G, France CP, Traynor JR (2003) Evaluation of new compounds for opioid activity. In: Dewey WL, Harris LS (eds) Problems of drug dependence: Proceedings of the 64th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc. National Institute on Drug Abuse Monograph Series 183. DHHS, Rockville, MD, pp 170–190
Zacny JP (2003) Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology 165:146–156
Zacny JP, Lichtor JL, Zaragoza JG, de Wit H (1992) Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology 107:319–326
Zacny JP, Lichtor JL, Binstock W, Coalson DW, Cutter T, Flemming DC, Glosten B (1993) Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. Psychopharmacology 111:306–314
Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C (2003) College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 69:215–232
Acknowledgements
Research was supported in part by grant R37 DA08573 from the National Institute on Drug Abuse. We thank the many anesthesiologists, anesthesiology residents, and nurse anesthetists for administering the drugs and monitoring the physiological status of the subjects, Karin Kirulis for screening potential subjects and conducting the structured interviews, and Dr. Diana Walker for her thoughtful critique of previous drafts of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zacny, J.P., Gutierrez, S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 170, 242–254 (2003). https://doi.org/10.1007/s00213-003-1540-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1540-9